AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well as a peptide synthesis, screening and optimization platform to strengthen AbbVie's pipeline and R&D capabilities ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...

Gifting allows recipients to access the article for free. Pharmaceutical giant AbbVie has inked another collaboration deal with an emerging biotech company as it seeks ways to bulk up its drug ...

Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers ... its platform and programs—and grow its research ...

The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...

The market outlook is as uncertain as it gets. On January 18, Robert Pavlik, senior portfolio manager at Dakota Wealth Management, appeared in an interview on Wealth at Yahoo Finance to share his ...

"A total of ten programs are currently in phase 3 clinical development..." Today, AbbVie employs approximately 21,000 people. The company's CEO and Chairman of the Board is Richard A. Gonzalez.

It was not immediately known how the federal funding freeze would affect W.I.C., which provides vouchers for healthy foods to ...

Robert F. Kennedy Jr. will face his first vetting by lawmakers this morning when Senate Finance Committee members are sure to ...